List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10032498/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. Journal of Affective Disorders, 2016, 190, 264-271.	2.0	601
2	Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Annals of Translational Medicine, 2015, 3, 136.	0.7	593
3	Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 41, 615-631.	1.2	363
4	Meta-analysis of modifiable risk factors for Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, jnnp-2015-310548.	0.9	354
5	Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Research Reviews, 2019, 55, 100944.	5.0	314
6	Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1201-1209.	0.9	258
7	Upregulation of TREM2 Ameliorates Neuropathology and Rescues Spatial Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease. Neuropsychopharmacology, 2014, 39, 2949-2962.	2.8	226
8	The NLRP3 Inflammasome in Alzheimer's Disease. Molecular Neurobiology, 2013, 48, 875-882.	1.9	225
9	Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 476-484.	0.9	224
10	Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 135-143.	0.9	217
11	Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy. Neurobiology of Aging, 2014, 35, 941-957.	1.5	204
12	Genome-Wide Serum microRNA Expression Profiling Identifies Serum Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 1017-1027.	1.2	186
13	Circulating miR-125b as a biomarker of Alzheimer's disease. Journal of the Neurological Sciences, 2014, 336, 52-56.	0.3	184
14	Efficacy and Adverse Effects of Ginkgo Biloba for Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 43, 589-603.	1.2	173
15	Dietary Patterns and Risk of Dementia: a Systematic Review and Meta-Analysis of Cohort Studies. Molecular Neurobiology, 2016, 53, 6144-6154.	1.9	172
16	Education and Risk of Dementia: Dose-Response Meta-Analysis of Prospective Cohort Studies. Molecular Neurobiology, 2016, 53, 3113-3123.	1.9	162
17	Temsirolimus promotes autophagic clearance of amyloid-β and provides protective effects in cellular and animal models of Alzheimer's disease. Pharmacological Research, 2014, 81, 54-63.	3.1	157
18	Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease. Trends in Molecular Medicine, 2013, 19, 594-603.	3.5	153

#	Article	IF	CITATIONS
19	NLRP1 inflammasome is activated in patients with medial temporal lobe epilepsy and contributes to neuronal pyroptosis in amygdala kindling-induced rat model. Journal of Neuroinflammation, 2015, 12, 18.	3.1	138
20	Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy. Scientific Reports, 2015, 5, 9522.	1.6	126
21	Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy. Scientific Reports, 2015, 5, 10201.	1.6	126
22	Midlife Vascular Risk Factors and the Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2014, 42, 1295-1310.	1.2	125
23	Depression in Alzheimer's Disease: Epidemiology, Mechanisms, and Management. Journal of Alzheimer's Disease, 2014, 42, 739-755.	1.2	98
24	Resveratrol as a Therapeutic Agent for Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-13.	0.9	97
25	Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Alzheimer's Research and Therapy, 2018, 10, 126.	3.0	97
26	Temsirolimus attenuates tauopathy inÂvitro and inÂvivo by targeting tau hyperphosphorylation and autophagic clearance. Neuropharmacology, 2014, 85, 121-130.	2.0	96
27	Serum Iron, Zinc, and Copper Levels in Patients with Alzheimer's Disease: A Replication Study and Meta-Analyses. Journal of Alzheimer's Disease, 2015, 47, 565-581.	1.2	94
28	Inhibition of the NLRP3 inflammasome provides neuroprotection in rats following amygdala kindling-induced status epilepticus. Journal of Neuroinflammation, 2014, 11, 212.	3.1	87
29	Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiology of Aging, 2014, 35, 1243-1251.	1.5	83
30	Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiology of Aging, 2015, 36, 3176-3186.	1.5	81
31	Matrix Metalloproteinases and Their Multiple Roles in Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-8.	0.9	79
32	Behavioral and Psychological Symptoms in Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-9.	0.9	75
33	NLRP3 polymorphisms are associated with late-onset Alzheimer's disease in Han Chinese. Journal of Neuroimmunology, 2013, 265, 91-95.	1.1	74
34	A rare coding variant in TREM2 increases risk for Alzheimer's disease in Han Chinese. Neurobiology of Aging, 2016, 42, 217.e1-217.e3.	1.5	71
35	IL12/23 p40 Inhibition Ameliorates Alzheimer's Disease-Associated Neuropathology and Spatial Memory in SAMP8 Mice. Journal of Alzheimer's Disease, 2013, 38, 633-646.	1.2	69
36	Heat Shock Protein 90 in Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-7.	0.9	66

#	Article	IF	CITATIONS
37	The Role of TDP-43 in Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 3349-3359.	1.9	66
38	Heat Shock Protein 70 in Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-8.	0.9	59
39	Triggering receptor expressed on myeloid cells 2 variant is rare in late-onset Alzheimer's disease in Han Chinese individuals. Neurobiology of Aging, 2014, 35, 937.e1-937.e3.	1.5	55
40	Genetics of Vascular Dementia: Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2015, 46, 611-629.	1.2	54
41	The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy. Molecular Neurobiology, 2016, 53, 4893-4904.	1.9	52
42	Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. Scientific Reports, 2016, 6, 26027.	1.6	48
43	Microglia in Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-7.	0.9	45
44	PGRN Is Associated with Late-Onset Alzheimer's Disease: a Case–Control Replication Study and Meta-analysis. Molecular Neurobiology, 2017, 54, 1187-1195.	1.9	40
45	Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration. Journal of Alzheimer's Disease, 2016, 52, 179-190.	1.2	39
46	Associations of Alzheimer's disease risk variants with gene expression, amyloidosis, tauopathy, and neurodegeneration. Alzheimer's Research and Therapy, 2021, 13, 15.	3.0	38
47	Genome-wide association study identifies Alzheimer's risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels. Neurobiology of Aging, 2019, 84, 241.e13-241.e20.	1.5	35
48	Genetic variation in BIN1 gene and Alzheimer's disease risk in Han Chinese individuals. Neurobiology of Aging, 2014, 35, 1781.e1-1781.e8.	1.5	33
49	Association of IL-12A and IL-12B polymorphisms with Alzheimer's disease susceptibility in a Han Chinese population. Journal of Neuroimmunology, 2014, 274, 180-184.	1.1	33
50	Association of HLA-DRB1 polymorphism with Alzheimer's disease: a replication and meta-analysis. Oncotarget, 2017, 8, 93219-93226.	0.8	33
51	The Role of Reelin Signaling in Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 5692-5700.	1.9	30
52	Application of next-generation sequencing technologies in Neurology. Annals of Translational Medicine, 2014, 2, 125.	0.7	28
53	Effect of EPHA1 Genetic Variation on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts. Journal of Alzheimer's Disease, 2015, 44, 115-123.	1.2	25
54	ZCWPW1 is associated with late-onset Alzheimer's disease in Han Chinese: a replication study and meta-analyses. Oncotarget, 2016, 7, 20305-20311.	0.8	24

#	Article	IF	CITATIONS
55	Genetic Association of HLA Gene Variants with MRI Brain Structure in Alzheimer's Disease. Molecular Neurobiology, 2017, 54, 3195-3204.	1.9	24
56	Association of Parkinson's Disease GWAS-Linked Loci with Alzheimer's Disease in Han Chinese. Molecular Neurobiology, 2017, 54, 308-318.	1.9	22
57	GWAS-Linked Loci and Neuroimaging Measures in Alzheimer's Disease. Molecular Neurobiology, 2017, 54, 146-153.	1.9	22
58	Soluble TREM1 concentrations are increased and positively correlated with total tau levels in the plasma of patients with Alzheimer's disease. Aging Clinical and Experimental Research, 2019, 31, 1801-1805.	1.4	21
59	Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia. Alzheimer's Research and Therapy, 2020, 12, 55.	3.0	21
60	Genetic variation in PICALM and Alzheimer's disease risk in Han Chinese. Neurobiology of Aging, 2014, 35, 934.e1-934.e3.	1.5	20
61	The Role of PGRN in Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 4189-4196.	1.9	20
62	The Association of MME microRNA Binding Site Polymorphism with the Risk of Late Onset Alzheimer's Disease in Northern Han Chinese. Current Neurovascular Research, 2017, 14, 90-95.	0.4	20
63	Heat Shock Proteins at the Crossroads between Cancer and Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-9.	0.9	19
64	Common Variants in PLD3 and Correlation to Amyloid-Related Phenotypes in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 491-495.	1.2	19
65	The Impact of UNC5C Genetic Variations on Neuroimaging in Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 6759-6767.	1.9	19
66	Genome-wide association studies in neurology. Annals of Translational Medicine, 2014, 2, 124.	0.7	18
67	Common variant in PTK2B is associated with late-onset Alzheimer's disease: A replication study and meta-analyses. Neuroscience Letters, 2016, 621, 83-87.	1.0	17
68	Effect of CR1 Genetic Variants on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts. Molecular Neurobiology, 2017, 54, 551-562.	1.9	17
69	Effects of HLA-DRB1/DQB1 Genetic Variants on Neuroimaging in Healthy, Mild Cognitive Impairment, and Alzheimer's Disease Cohorts. Molecular Neurobiology, 2017, 54, 3181-3188.	1.9	17
70	Rare Variants in PLD3 Increase Risk for Alzheimer's Disease in Han Chinese. Journal of Alzheimer's Disease, 2018, 64, 55-59.	1.2	17
71	Decreased expression of CD33 in peripheral mononuclear cells of Alzheimer's disease patients. Neuroscience Letters, 2014, 563, 51-54.	1.0	16
72	ABCA7 Genotypes Confer Alzheimer's Disease Risk by Modulating Amyloid-β Pathology. Journal of Alzheimer's Disease, 2016, 52, 693-703.	1.2	16

#	Article	IF	CITATIONS
73	Impacts of CD33 Genetic Variations on the Atrophy Rates of Hippocampus and Parahippocampal Gyrus in Normal Aging and Mild Cognitive Impairment. Molecular Neurobiology, 2017, 54, 1111-1118.	1.9	16
74	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. Journal of Alzheimer's Disease, 2016, 51, 227-236.	1.2	14
75	Association of Single-Nucleotide Polymorphism in ANK1 with Late-Onset Alzheimer's Disease in Han Chinese. Molecular Neurobiology, 2016, 53, 6476-6481.	1.9	14
76	Impact of Common Variations in PLD3 on Neuroimaging Phenotypes in Non-demented Elders. Molecular Neurobiology, 2016, 53, 4343-4351.	1.9	13
77	The Role of Retromer in Alzheimer's Disease. Molecular Neurobiology, 2016, 53, 4201-4209.	1.9	13
78	A Missense Variant in TREML2 Reduces Risk of Alzheimer's Disease in a Han Chinese Population. Molecular Neurobiology, 2017, 54, 977-982.	1.9	13
79	The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum. Scientific Reports, 2016, 6, 24480.	1.6	11
80	Frontotemporal Lobar Degeneration: Mechanisms and Therapeutic Strategies. Molecular Neurobiology, 2016, 53, 6091-6105.	1.9	11
81	HLA-A2 Alleles Mediate Alzheimer's Disease by Altering Hippocampal Volume. Molecular Neurobiology, 2017, 54, 2469-2476.	1.9	11
82	<i>MEF2C</i> rs190982 polymorphism with late-onset Alzheimer's disease in Han Chinese: A replication study and meta-analyses. Oncotarget, 2016, 7, 39136-39142.	0.8	11
83	Association of LRRTM3 polymorphisms with late-onset Alzheimer's disease in Han Chinese. Experimental Gerontology, 2014, 52, 18-22.	1.2	10
84	Endovascular Treatment Versus Intravenous Thrombolysis for Acute Ischemic Stroke: a Quantitative Review and Meta-Analysis of 21 Randomized Trials. Molecular Neurobiology, 2017, 54, 1369-1378.	1.9	10
85	Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese. Oncotarget, 2016, 7, 22746-22751.	0.8	10
86	Impact of SORL1 genetic variations on MRI markers in non-demented elders. Oncotarget, 2016, 7, 31689-31698.	0.8	8
87	TREML2 Mutation Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration. Frontiers in Neuroscience, 2019, 13, 455.	1.4	8
88	FERMT2 rs17125944 polymorphism with Alzheimer's disease risk: a replication and meta-analysis. Oncotarget, 2016, 7, 39044-39050.	0.8	7
89	SORL1 Is Associated with the Risk of Late-Onset Alzheimer's Disease: a Replication Study and Meta-Analyses. Molecular Neurobiology, 2017, 54, 1725-1732.	1.9	7
90	Common Variant in PLD3 Influencing Cerebrospinal Fluid Total Tau Levels and Hippocampal Volumes in Mild Cognitive Impairment Patients from the ADNI Cohort. Journal of Alzheimer's Disease, 2018, 65, 871-876.	1.2	7

#	Article	IF	CITATIONS
91	<i>NME8</i> rs2718058 polymorphism with Alzheimer's disease risk: a replication and meta-analysis. Oncotarget, 2016, 7, 36014-36020.	0.8	7
92	Association of lectin-like oxidized low density lipoprotein receptor 1 (OLR1) polymorphisms with late-onset Alzheimer disease in Han Chinese. Annals of Translational Medicine, 2018, 6, 172-172.	0.7	7
93	Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. Oncotarget, 2016, 7, 13319-13327.	0.8	5
94	Association of DISC1 Polymorphisms with Late-Onset Alzheimer's Disease in Northern Han Chinese. Molecular Neurobiology, 2017, 54, 2922-2927.	1.9	4
95	PET Amyloid and Tau Status Are Differently Affected by Patient Features. Journal of Alzheimer's Disease, 2020, 78, 1129-1136.	1.2	4
96	Inhibition of caspase-1 ameliorates tauopathy and rescues cognitive impairment in SAMP8 mice. Metabolic Brain Disease, 2022, 37, 1197-1205.	1.4	4
97	Associations of rs3740677 within GAB2 Gene with LOAD in Chinese Han Population. Molecular Neurobiology, 2017, 54, 4015-4020.	1.9	2
98	Caspase-1 variant influencing CSF tau and FDG PET levels in non-demented elders from the ADNI cohort. BMC Neurology, 2022, 22, 59.	0.8	1